PrecivityAD®
Use
The PrecivityAD test is intended for use in patients 50 and older with signs or symptoms of mild cognitive impairment or dementia. It aids healthcare providers in detecting amyloid plaques in the brain, indicative of Alzheimer's disease pathology, and informs medical management and treatment decisions. The test is clinically validated and offers a non-invasive means to assess Alzheimer's disease with high accuracy, providing insights that can help guide patient care.
Special Instructions
Not provided.
Limitations
The test is not designed to diagnose Alzheimer's disease on its own but to provide a probability score indicative of amyloid plaque presence, which is a hallmark of Alzheimer's pathology. Test performance may be affected by patient demographics and comorbidities. The presence of amyloid plaques is not exclusive to Alzheimer's and can occur in other conditions.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
Aβ42
Proteinp-tau217
Protein
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
7 mL
Container
Lavender top (EDTA) tube
Collection Instructions
Blood samples should be collected in EDTA tubes and shipped promptly under frozen conditions to ensure stability.
Patient Preparation
Patients are not required to fast before the blood draw.
Storage Instructions
Store the specimen frozen from the time of collection until it is shipped to the testing lab.
Causes for Rejection
Improper labeling, hemolysis, lipemia, or insufficient specimen volume.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 30 days |